Cargando…
Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective
Coronavirus disease of 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly the world over. The disease was declared “pandemic” by the World Health Organization. An approved therapy for patients with COVID-19 has yet to emerge; howeve...
Autores principales: | Talasaz, Azita Hajhossein, Kakavand, Hessam, Van Tassell, Benjamin, Aghakouchakzadeh, Maryam, Sadeghipour, Parham, Dunn, Steven, Geraiely, Babak |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360896/ https://www.ncbi.nlm.nih.gov/pubmed/32671601 http://dx.doi.org/10.1007/s10557-020-07037-2 |
Ejemplares similares
-
The Potential Role of Clinical Pharmacy Services in Patients with Cardiovascular Diseases
por: Talasaz, Azita Hajhossein
Publicado: (2012) -
Evaluating the role of intravenous pentoxifylline administration on primary percutaneous coronary intervention success rate in patients with ST-elevation myocardial infarction (PENTOS-PCI)
por: Kakavand, Hessam, et al.
Publicado: (2023) -
Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review
por: Talasaz, Azita H., et al.
Publicado: (2021) -
COVID-19 sends STEMI to quarantine!?
por: Abdi, Seifollah, et al.
Publicado: (2020) -
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review
por: Talasaz, Azita H., et al.
Publicado: (2021)